The Institute for Clinical and Economic Review (ICER) will leverage IPD Analytics’ (IPD) data and insights to bolster its reviews of “high-impact, high-cost therapies” as part of a new collaborative effort, the organizations announced last week.
The initiative was announced Thursday, May 9.
IPD brings to the table a “deep, informed and fully independent analysis” of the biopharmaceutical industry.
“IPD analytics is an unbiased, independent organization that works to drive efficiency and transparency in the prescription drug market,” ICER President Steven Pearson said in a statement. “We value their rigorous and thoughtful analysis of the drug pipeline and we look forward to using this information as a key resource to support our internal horizon scanning efforts and to inform our process for selecting assessment topics.”
To read the full press release on Newswire, click here.